Vertex Pharmaceuticals Incorporated (VRTX)

Market Cap	120.69B
Revenue (ttm)	11.72B +10.3%
Net Income	3.68B
EPS	14.22
Shares Out	253.72M
PE Ratio	33.45
Forward PE	23.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,497,628
Open	479.03
Previous Close	477.91
Day's Range	473.86 - 484.35
52-Week Range	362.50 - 519.68
Beta	0.31
Analysts	Buy
Price Target	512.63 (+7.77%)
Earnings Date	Feb 12, 2026

About VRTX

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 24, 1991
• Employees: 6,100
• Stock Exchange: NASDAQ
• Ticker Symbol: VRTX
• Website: https://www.vrtx.com

Analyst Summary

According to 27 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price target is $512.63, which is an increase of 7.77% from the latest price.

Price Target

$512.63

(7.77% upside)

Analyst Consensus: Buy